{"nctId":"NCT01780935","briefTitle":"Efficacy and Safety of Two Treatment Regimens of 0.5 mg Ranibizumab Intravitreal Injections Guided by Functional and/or Anatomical Criteria, in Patients With Neovascular Age-related Macular Degeneration","startDateStruct":{"date":"2013-06-03","type":"ACTUAL"},"conditions":["Neovascular Age-related Macular Degeneration"],"count":671,"armGroups":[{"label":"RBZ 0.5 mg: VA only (Group I)","type":"EXPERIMENTAL","interventionNames":["Drug: Ranibizumab"]},{"label":"RBZ 0.5 mg: VA and/or OCT (Group II)","type":"EXPERIMENTAL","interventionNames":["Drug: Ranibizumab"]}],"interventions":[{"name":"Ranibizumab","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Visual impairment predominantly due to neovascular age-related macular degeneration AMD\n* Active, newly diagnosed, untreated CNV due to AMD\n* CNV involving the center of the retina\n* A qualifying vision score at study entry\n\nExclusion Criteria:\n\n* Stroke or myocardial infarction less than 3 Months prior to study entry\n* Active injection or inflammation of either eye at the time of study entry","healthyVolunteers":false,"sex":"ALL","minimumAge":"50 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Average Best-corrected Visual Acuity (BCVA) (Letters) Change up to Month 12","description":"Visual acuity (VA) was assessed during every study visit using best correction determined from protocol refraction. VA measurements (number of letters correctly identified) were performed with the patient in a sitting position using Early Treatment Diabetic Retinopathy Study (ETDRS)-like VA testing charts at a testing distance of 4 meters. This outcome measure describes the difference between the Visual Acuity averaged up to Month 12 Level of VA (Letters) of the Study Eye.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.1","spread":"6.79"},{"groupId":"OG001","value":"1.0","spread":"7.25"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Visual Acuity (Letters) of the Study Eye up to Month 12","description":"Visual acuity (VA) was assessed using best correction determined from protocol refraction. VA measurements (number of letters correctly identified) were performed with the patient in a sitting position using Early Treatment Diabetic Retinopathy Study (ETDRS)-like VA testing charts at a testing distance of 4 meters. This outcome measure describes the difference between the Visual Acuity averaged from Baseline to Month 12 Level of VA (Letters) of the Study Eye.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.7","spread":"13.48"},{"groupId":"OG001","value":"8.3","spread":"13.53"}]}]}]},{"type":"SECONDARY","title":"Gain of Equal or More Than 1, 5, 10, or 15 Letters in Visual Acuity of the Study Eye From Baseline, at Month 12 and 24","description":"During the course of the study, the use of optical coherence tomography (OCT)-guided therapy became a standard of care accepted by health authorities and the ophthalmology community in the treatment of neovascular (wet) age-related macular degeneration (nAMD), Novartis decided on 08-Oct-2014 the early termination of the study. Therefore the 12-month cutoff date was not reached and the related analyses were not performed.","classes":[]},{"type":"SECONDARY","title":"Loss of Less Than 5, 10, and 15 Letters in Visual Acuity in the Study Eye From Baseline, at Month 12 and 24","description":"During the course of the study, the use of optical coherence tomography (OCT)-guided therapy became a standard of care accepted by health authorities and the ophthalmology community in the treatment of neovascular (wet) age-related macular degeneration (nAMD), Novartis decided on 08-Oct-2014 the early termination of the study. Therefore the 12-month cutoff date was not reached and the related analyses were not performed.","classes":[]},{"type":"SECONDARY","title":"Visual Acuity of 73 Letters or More in the Study Eye at Month 12 and 24","description":"During the course of the study, the use of optical coherence tomography (OCT)-guided therapy became a standard of care accepted by health authorities and the ophthalmology community in the treatment of neovascular (wet) age-related macular degeneration (nAMD), Novartis decided on 08-Oct-2014 the early termination of the study. Therefore the 12-month cutoff date was not reached and the related analyses were not performed.","classes":[]},{"type":"SECONDARY","title":"Average Visual Acuity Change From Month 3 to Month 4 Through Month 24 in the Study Eye","description":"During the course of the study, the use of optical coherence tomography (OCT)-guided therapy became a standard of care accepted by health authorities and the ophthalmology community in the treatment of neovascular (wet) age-related macular degeneration (nAMD), Novartis decided on 08-Oct-2014 the early termination of the study. Therefore the 12-month cutoff date was not reached and the related analyses were not performed.","classes":[]},{"type":"SECONDARY","title":"Average Visual Acuity Change From Baseline to Month 1 Through Month 12 and 24 in the Study Eye","description":"During the course of the study, the use of optical coherence tomography (OCT)-guided therapy became a standard of care accepted by health authorities and the ophthalmology community in the treatment of neovascular (wet) age-related macular degeneration (nAMD), Novartis decided on 08-Oct-2014 the early termination of the study. Therefore the 12-month cutoff date was not reached and the related analyses were not performed.","classes":[]},{"type":"SECONDARY","title":"Change From Baseline in Central Sub-Field Thickness (CSFT) and Central Sub-Field Volume (CSFV) of the Study Eye Over Time","description":"During the course of the study, the use of optical coherence tomography (OCT)-guided therapy became a standard of care accepted by health authorities and the ophthalmology community in the treatment of neovascular (wet) age-related macular degeneration (nAMD), Novartis decided on 08-Oct-2014 the early termination of the study. Therefore the 12-month cutoff date was not reached and the related analyses were not performed.","classes":[]},{"type":"SECONDARY","title":"Dry Retina in the Study Eye on OCT at Month 12 and 24","description":"During the course of the study, the use of optical coherence tomography (OCT)-guided therapy became a standard of care accepted by health authorities and the ophthalmology community in the treatment of neovascular (wet) age-related macular degeneration (nAMD), Novartis decided on 08-Oct-2014 the early termination of the study. Therefore the 12-month cutoff date was not reached and the related analyses were not performed.","classes":[]},{"type":"SECONDARY","title":"Change From Baseline in Lesion Size and Morphology Based on Fluorescein Angiography at Month 12 and 24","description":"During the course of the study, the use of optical coherence tomography (OCT)-guided therapy became a standard of care accepted by health authorities and the ophthalmology community in the treatment of neovascular (wet) age-related macular degeneration (nAMD), Novartis decided on 08-Oct-2014 the early termination of the study. Therefore the 12-month cutoff date was not reached and the related analyses were not performed.","classes":[]},{"type":"SECONDARY","title":"Treatment Patterns Over Time in Both Treatment Arms","description":"During the course of the study, the use of optical coherence tomography (OCT)-guided therapy became a standard of care accepted by health authorities and the ophthalmology community in the treatment of neovascular (wet) age-related macular degeneration (nAMD), Novartis decided on 08-Oct-2014 the early termination of the study. Therefore the 12-month cutoff date was not reached and the related analyses were not performed.","classes":[]},{"type":"SECONDARY","title":"Change From Baseline in the National Eye Institute Visual Functioning Questionnaire (NEI-VFQ-25) Scores Over Time","description":"During the course of the study, the use of optical coherence tomography (OCT)-guided therapy became a standard of care accepted by health authorities and the ophthalmology community in the treatment of neovascular (wet) age-related macular degeneration (nAMD), Novartis decided on 08-Oct-2014 the early termination of the study. Therefore the 12-month cutoff date was not reached and the related analyses were not performed.","classes":[]},{"type":"SECONDARY","title":"Frequency and Severity of Ocular and Non-ocular Adverse Events Over Time","description":"During the course of the study, the use of optical coherence tomography (OCT)-guided therapy became a standard of care accepted by health authorities and the ophthalmology community in the treatment of neovascular (wet) age-related macular degeneration (nAMD), Novartis decided on 08-Oct-2014 the early termination of the study. Therefore the 12-month cutoff date was not reached and the related analyses were not performed.","classes":[]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":30,"n":334},"commonTop":["Nasopharyngitis","Intraocular pressure increased (Study eye)","Hypertension","Influenza","Conjunctival haemorrhage (Study eye)"]}}}